Australian M&A and equity raisings

2,041 deals since January 2025, with sources and adviser credits where available · as at 20 Nov 2026 · Venture rounds

Deal size
Custom range

4 deals · A$32.8mdisclosed · Biotech · Clear

Columns
Australian M&A deals and equity raisings
Date Target Vendor Acquirer Type Status Value A$m Sector Advisers
Mar 2026 Imugene ––PlacementCompleted20.0Biotech+1 McCullough Robertson (issuer)E&P Capital (lead manager)Barrenjoey (lead manager)Bell Potter (lead manager)
Jan 2026 AdAlta ––PlacementCompleted1.2Biotech+1 Sixty Two Capital (lead manager)
Sep 2025 Neurizon Therapeutics ––PlacementCompleted5.0Biotech+1 Petra Capital (lead manager)
May 2025 Chimeric Therapeutics ––PlacementAnnounced6.6Biotech+2 PAC Partners (lead manager)Taylor Collison (lead manager)

Deals come from ASX announcements, scheme booklets, prospectuses, the advisers' own deal announcements and the press. How the data is built